# Mesenchymal Stem Cell Sheet Engineering: Refining Cell Delivery Strategies in Regenerative Medicine

## TL;DR

This paper reviews how engineering mesenchymal stem cell sheets improves regenerative therapies by enabling sustained tissue repair compared to traditional single-cell approaches.

## Contribution

The paper introduces MSC sheet engineering as a conceptual shift toward structurally integrated, tissue-level regeneration.

## Key findings

- MSC sheets enhance cell retention and promote tissue-level regeneration in preclinical models.
- Effective MSC sheet therapy requires organ-specific and cell-source-dependent design strategies.
- Cell sheet technology offers sustained paracrine signaling and better therapeutic persistence compared to single-cell delivery.

## Abstract

MSC sheet engineering addresses fundamental limitations of transient single-cell therapies by enabling sustained, tissue-integrated regeneration rather than short-lived paracrine effects.

MSC sheet platform reframes MSC-based treatment from inflammation-modulating approaches toward structurally and functionally regenerative therapies.

From this perspective, manufacturing and quality control emerge as core drives for the clinical translation of MSC sheet-based, truly regenerative cell therapies.

Mesenchymal stem cells (MSCs) have been widely investigated in regenerative medicine owing to their immunomodulatory activity, paracrine signaling, and multilineage differentiation potential. However, accumulating clinical and preclinical evidence indicates that conventional MSC therapies based on single-cell injection often produce transient benefits due to rapid post-transplant cell loss and poor engraftment. These observations suggest that the limited efficacy of MSC therapy is not determined solely by cell type or disease context but may also be influenced by the delivery strategy. In this review, we focus on MSC-based cell sheet studies as an approach to improve cell retention and therapeutic persistence. Building on the clinical validation of cell sheet technology, we critically summarize preclinical evidence across distinct tissue environments. Preclinical studies in cardiac and cutaneous repair models demonstrate that MSC sheets enhance cell retention, sustain paracrine signaling, and promote tissue-level regeneration. Together, these findings highlight that effective MSC sheet therapy requires organ-specific, cell-source-dependent design strategies rather than a uniform approach across tissues. Finally, we propose that the MSC sheet engineering represents not a technical adjustment, but a conceptual shift from transient cell delivery toward structurally integrated, tissue-level regeneration engineering.